Endometrial Neoplasms Clinical Trial
Official title:
A Randomized Phase II Study of Lenvatinib Versus Doxorubicin in Second Line Advanced or Recurrent Endometrial Carcinoma
The primary objective of this multicenter, randomized phase II trial is to assess the
efficacy, as measured by progression-free survival (PFS), of lenvatinib compared to
doxorubicin in advanced or recurrent endometrial cancer.
The main secondary objective is to evaluate the predictive value of Ang-2 on lenvatinib
activity and establishing a cutoff value as potential selection criteria for phase III.
Other secondary objectives are to assess the tolerability and safety of lenvatinib in this
setting and overall survival, response and disease control.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | July 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Female subjects age =18 years at the time of informed consent - World Health Organization (WHO) Performance Status of 0 or 1 - Patients with histologically confirmed endometrial cancer including serous-papillary and clear cell histologies. Uterine carcinosarcomas are allowed. - Radiographic evidence of disease progression according to RECIST 1.1 after 1 prior systemic, platinum-based chemotherapy regimen for metastatic or primary unresectable endometrial carcinoma for which no surgical or radiotherapy treatment options exist. - Patients with disease progression following platinum-based chemotherapy administered as either adjuvant or neoadjuvant treatment are also eligible. - Patients may have received prior radiotherapy and / or adjuvant chemotherapy for early high-risk disease - Patients may not have received prior treatment with anthracyclines - Blood samples available for retrospective central assessment of Ang-2 level - Patients may have had prior therapy providing the following conditions are met: - Surgery and radiation therapy: wash-out period of 14 days and subjects must have recovered adequately from any toxicity and/or complications from radiotherapy and major surgery prior to starting therapy. - Systemic anti-tumor therapy or any investigational agent: wash-out period of 21 days (or 5 x half-life) - Recovery from any toxic effects of prior therapy to = Grade 1 per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v4.) except alopecia - Adequate contraceptive measures - Signed written informed consent Exclusion Criteria: - Inadequate hematologic, renal and hepatic functions - Abnormal cardiac function |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Switzerland | Centre Hospitalier Universitaire Vaudois | Lausanne |
Lead Sponsor | Collaborator |
---|---|
European Organisation for Research and Treatment of Cancer - EORTC |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression free survival (PFS) | PFS assessed by Response Evaluation Criteria in Solid Tumors (RECIST | 2.5 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06409039 -
POLE-END REAL LIFE: Endometrial Cancer Early Stages I-II and Advanced Stages III and IV Evaluation of POLE as a Prognostic Factor. Participants Are Women >= 18 Years Old, With the Pole Mutation
|
||
Completed |
NCT02865889 -
Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications
|
N/A | |
Completed |
NCT00377520 -
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05682950 -
Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05974995 -
Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer
|
N/A | |
Recruiting |
NCT03291275 -
Survival Outcomes of Uterine Malignancies in Chinese Population
|
N/A | |
Recruiting |
NCT03291106 -
Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer
|
||
Completed |
NCT00341458 -
Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics
|
||
Terminated |
NCT05067972 -
A Study of PF-07260437 in Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05795244 -
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)
|
Phase 2 | |
Recruiting |
NCT05770102 -
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04865289 -
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
|
Phase 3 | |
Completed |
NCT03270995 -
Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study
|
N/A | |
Terminated |
NCT01969396 -
Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology
|
N/A | |
Completed |
NCT01460979 -
Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT05869123 -
Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Active, not recruiting |
NCT05588076 -
Endometrial Lesions Predictions
|